Nice_老虎社区_美港股上老虎

blaCkbOx
2021-09-28

Nice

Pfizer submits data to FDA for COVID-19 vaccine in younger children

Sept 28 (Reuters) - Pfizer Inc and BioNTech SE submitted initial trial data for their COVID-19 vacci

Pfizer submits data to FDA for COVID-19 vaccine in younger children

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":862927513,"tweetId":"862927513","gmtCreate":1632832350582,"gmtModify":1632832350715,"author":{"id":3574676557290827,"idStr":"3574676557290827","authorId":3574676557290827,"authorIdStr":"3574676557290827","name":"blaCkbOx","avatar":"https://static.tigerbbs.com/2e60934f569874a5dfc7a83e2074f311","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":15,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Nice</p></body></html>","htmlText":"<html><head></head><body><p>Nice</p></body></html>","text":"Nice","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/862927513","repostId":2170670898,"repostType":2,"repost":{"id":"2170670898","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1632827036,"share":"https://www.laohu8.com/m/news/2170670898?lang=&edition=full","pubTime":"2021-09-28 19:03","market":"us","language":"en","title":"Pfizer submits data to FDA for COVID-19 vaccine in younger children","url":"https://stock-news.laohu8.com/highlight/detail?id=2170670898","media":"Reuters","summary":"Sept 28 (Reuters) - Pfizer Inc and BioNTech SE submitted initial trial data for their COVID-19 vacci","content":"<p>Sept 28 (Reuters) - Pfizer Inc and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> submitted initial trial data for their COVID-19 vaccine in children aged 5 to 11 to U.S. regulators on Tuesday and said they would make a formal request for emergency use authorization in the coming weeks.</p>\n<p>Coronavirus infections have soared in children and hit their highest point in early September, according to data from the American Academy of Pediatrics.</p>\n<p>The vaccine, which is already authorized in teens aged 12 to 15 and fully approved for ages 16 and up, has been shown to induce a strong immune response in the target age group in a 2,268-participant clinical trial, the companies said on Sept. 20.</p>\n<p>The Pfizer-BioNTech vaccine was authorized in kids aged 12-15 roughly a month after the companies filed for authorization. If the same timeline is followed for this application, kids could start receiving their shots as soon as late October.</p>\n<p>A rapid authorization could help mitigate a potential surge of cases this fall, with schools already open nationwide.</p>\n<p>While kids are less susceptible to severe COVID-19, they can spread the virus to others, including vulnerable populations that are more at risk of severe illness.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer submits data to FDA for COVID-19 vaccine in younger children</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer submits data to FDA for COVID-19 vaccine in younger children\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-28 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sept 28 (Reuters) - Pfizer Inc and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> submitted initial trial data for their COVID-19 vaccine in children aged 5 to 11 to U.S. regulators on Tuesday and said they would make a formal request for emergency use authorization in the coming weeks.</p>\n<p>Coronavirus infections have soared in children and hit their highest point in early September, according to data from the American Academy of Pediatrics.</p>\n<p>The vaccine, which is already authorized in teens aged 12 to 15 and fully approved for ages 16 and up, has been shown to induce a strong immune response in the target age group in a 2,268-participant clinical trial, the companies said on Sept. 20.</p>\n<p>The Pfizer-BioNTech vaccine was authorized in kids aged 12-15 roughly a month after the companies filed for authorization. If the same timeline is followed for this application, kids could start receiving their shots as soon as late October.</p>\n<p>A rapid authorization could help mitigate a potential surge of cases this fall, with schools already open nationwide.</p>\n<p>While kids are less susceptible to severe COVID-19, they can spread the virus to others, including vulnerable populations that are more at risk of severe illness.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170670898","content_text":"Sept 28 (Reuters) - Pfizer Inc and BioNTech SE submitted initial trial data for their COVID-19 vaccine in children aged 5 to 11 to U.S. regulators on Tuesday and said they would make a formal request for emergency use authorization in the coming weeks.\nCoronavirus infections have soared in children and hit their highest point in early September, according to data from the American Academy of Pediatrics.\nThe vaccine, which is already authorized in teens aged 12 to 15 and fully approved for ages 16 and up, has been shown to induce a strong immune response in the target age group in a 2,268-participant clinical trial, the companies said on Sept. 20.\nThe Pfizer-BioNTech vaccine was authorized in kids aged 12-15 roughly a month after the companies filed for authorization. If the same timeline is followed for this application, kids could start receiving their shots as soon as late October.\nA rapid authorization could help mitigate a potential surge of cases this fall, with schools already open nationwide.\nWhile kids are less susceptible to severe COVID-19, they can spread the virus to others, including vulnerable populations that are more at risk of severe illness.","news_type":1},"isVote":1,"tweetType":1,"viewCount":982,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}